CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its SYS6020. This investigational treatment is a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy intended for myasthenia gravis (MG). Notably, SYS6020 has previously been granted approval for trials in China for the treatment of multiple myeloma (MM) and systemic lupus erythematosus (SLE).
SYS6020 is hailed as the world’s first mRNA-LNP-based cell therapy to be approved for clinical trials. The therapy boasts high cell viability, a high CAR positivity rate, and is devoid of oncogenic risks associated with genome integration. Additionally, it exhibits low side effects, such as cytokine release syndrome (CRS), compared to traditional CAR-T products, positioning it as a potentially safer and more effective treatment option.- Flcube.com
